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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 























• Prognostic models to 
predict the risk of clinical 
deterioration in acute 
COVID-19 cases are 
urgently required to 
inform clinical 
management decisions 
• Here a 4C Deterioration 
model was developed 
and validated, including 
11 routinely measured 
demographic, clinical, 
and laboratory predictors, 




adults recruited to the 
ISARIC4C study across 
260 hospitals in England, 
Scotland and Wales. 
• The 4C Deterioration 
model has strong 
potential for clinical utility 
and generalisability to 
predict clinical 
deterioration and inform 





adults hospitalised with 
COVID-19 
• The 4C Deterioration tool 
offers additional value to 
the recently reported 4C 
Mortality Score, by 
identifying people at high 
risk of deterioration 
despite a low risk of 
mortality, with potential to 
better target interventions 
to those with most need 
and are most likely to 
benefit. 
• The 4C Deterioration 
model will be freely 
available online for 
external validation and to 
facilitate risk stratification 
for therapeutic 
intervention 



















• Most LMICs have 
little or no data 
integrated into a 
national 
surveillance 





admission and the 
impact of the 
COVID-19 
pandemic on their 
national health 
systems 
• This retrospective 
analysis of all 
hospitalised 
patients aged 20 










health system  








all regions in 
Brazil was 
observed, 





high, even in 
patients younger 
than 60 years, 
and worsened by 
existing regional 
disparities within 
the health system. 
COVID-19 
disproportionately 
affects not only 
the most 
vulnerable 
patients but also 
the most fragile 
health systems. 
• Improvement in 
access to high-
quality care for 
critically ill 
patients admitted 















• A predecessor to 
the B.1.1.7 “UK” 
variant was seen 
in Italy in August 
(N501T 












the end of Sept 
2020, when the 
rapidly emerging 
B.1.1.7 lineage 
was first reported 
11.01.2021 Estimates of 
severity and 
transmissibility 






print (not yet 
peer-reviewed) 
• On 18 Dec 2020, 
researchers 
reported 
emergence of a 
novel SARS-CoV-
2 variant , 
501Y.V2, in South 
Africa 
• Using globally 
available data, an 
evaluation of the 




immune escape is 
reported here 
• Authors estimate 
501Y.V2 is 1.50 
(95% CrI 1.20-





• Some evidence of 






• Along with the 
emergence of a 








global control in 








































• This systematic 
review and meta-
analysis found that 
saliva NAAT and 
nasopharyngeal 
NAAT had a similar 
sensitivity and 
specificity  
• Given the ease of 
use and comparable 
diagnostic accuracy, 




swab NAAT which 
may help increase 
mass testing efforts 






















• The DMC of the 
RECOVERY trial 
reviewed data on 
patients randomised to 
convalescent plasma vs 
usual care. Preliminary 
analysis of 10,406 
randomised patients 
with 1873 reported 
deaths shows no 





the primary endpoint of 
28-day mortality 
• 18% convalescent 
plasma vs 18% usual 
care alone; RR 1.04 
[95% CI 0.95-1.14]; 
p=0.34 
• Follow-up of patients is 
ongoing and final 
results will be published 
as soon as possible 
• Whilst the overall result 
is negative, full results 
are required to 
determine if there is any 
benefit in particular 
patient subgroups 
• Note RECOVERY 
continues to study the 
REGN-CoV2 
monoclonal antibody 
cocktail – shown to 
have benefit in RCTs in 
early COVID. In Ebola, 
convalescent plasma 






levels and the 
risk of deaths 
from Covid-19 
NEJM | Article 
• A retrospective study 
based on a U.S. 
national registry, of anti-
SARS-CoV-2 IgG 
antibody levels in 
convalescent plasma 
used to treat 3082 
hospitalised adults with 
Covid-19. Primary 
outcome was death 
within 30 days after 
plasma transfusion 
• No effect on the risk of 
death was observed 
among patients who 
had received 
mechanical ventilation 
• Among patients who 
were not receiving 
mechanical ventilation, 
transfusion of plasma 
with higher anti-SARS-
CoV-2 IgG antibody 
levels was associated 
with a lower risk of 
death than transfusion 
Convalescent 
plasma 








13.01.2021 Interim results 
of a phase 1-




NEJM | Article 
• Candidate vaccine, 





26 vector encoding a 
full-length and 
stabilised SARS-CoV-
2 spike protein 
• Multicentre, placebo-
controlled, phase 1-2a 
trial of two age groups 
receiving a low or high 
dose of the vaccine 
candidate or placebo 
in a single-dose or 
two-dose schedule 
• The safety and 
immunogenicity 
profiles support further 







Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
18.01.2021 UK funded research essential to get vaccines to 
the poorest in the world 
Open Access Government | 
Blog 
17.01.2021 Equitable recovery from COVID-19: bring global 
commitments to community level 
BMJ Global Health | 
Commentary 
15.01.2021 China COVID vaccine reports mixed results – 
what does that mean for the pandemic? 
Nature | News 
13.01.2021 2021: a new year for the WHO Nature Medicine | Editorial 
13.01.2021 Women and children last? Shaking up exclusion 
criteria for vaccine trials 
Nature Medicine | World View 
13.01.2021 On the origins of SARS-CoV-2 Nature Medicine | World View 
13.01.2021 Immune determinants of COVID-19 disease 
presentation and severity 
Nature Medicine | Perspective 
   
 
Dashboards & Trackers 












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 





US NIH   Our World in 
Data: C19 
Testing 






Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 






















LSTM Stop TB 
Partnership 








  IDA 





ICL MRC Centre for Global 
































Johns Hopkins University RBM 
Partnership 





















UN Women Africa 
Evidence 
Network 












Norwegian Institute of 
Public Health 
    






Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   The 
Lancet 
 HEART     





 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
Universit
y Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent Epidemics      
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprint
s)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
Online event 1h30 CGD 
before we approve 
efficacious COVID-19 
vaccines 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 












online brief with Dr 
David Nabarro 














training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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